J&J Launches VARIPULSE Pro in Europe, Accelerating PFA Adoption
Event summary
- Johnson & Johnson received CE Mark approval and launched VARIPULSE Pro in Europe.
- VARIPULSE Pro utilizes a new pulse sequence that is 5x faster than the previous sequence while maintaining equivalent lesion size.
- The new platform integrates with the CARTO 3 System for advanced mapping and lesion delivery.
- Initial cases are being performed under the VARIPURE multicenter study, with 12-month interim results to be presented at EHRA.
The big picture
The European launch of VARIPULSE Pro underscores J&J’s commitment to expanding its presence in the rapidly growing pulsed field ablation market, which addresses the significant unmet need in atrial fibrillation treatment. PFA represents a less invasive alternative to traditional ablation procedures, and J&J’s integration with the CARTO mapping system aims to enhance precision and efficiency. The company’s focus on generating rigorous clinical evidence will be crucial for driving adoption and solidifying its leadership position in this space.
What we're watching
- Clinical Adoption
- The success of VARIPULSE Pro will depend on the speed and quality of data generated by the VARIPURE study and subsequent clinical trials, which will influence physician adoption.
- US Approval
- The timeline for FDA approval in the United States remains uncertain, and will be a key indicator of the platform’s overall potential.
- Competitive Landscape
- The emergence of competing PFA technologies could erode J&J’s market share if VARIPULSE Pro’s advantages are not clearly demonstrated and sustained.
Related topics